Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia

Leukemia

Volumn 15, Issue 10, 2001, Pages 1544-1553

  Van Der Kolk, D M ^a   De Vries, E G E ^a   Noordhoek, L ^b   Van Den Berg, E ^b   Van Der Pol, M A ^c   Muller M ^a   Vellenga, E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia (AML); Multidrug resistance proteins (MRPs); P glycoprotein (P gp); Relapse

Indexed keywords

AMSACRINE; CARBOXYFLUORESCEIN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MESSENGER RNA; MITOXANTRONE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; VALSPODAR; VERLUKAST;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TRANSPORT; FLOW CYTOMETRY; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENETIC REGULATION; HUMAN; HUMAN CELL; KARYOTYPING; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034777851     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402236     Document Type: Article

References (53)

1. Multidrug resistance (MDR1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
2. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
3. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
4. Frequency and clinical significance of the expression of the multi-drug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: A southwest Oncology Group Study
5. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications
6. JC-1: A very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia
7. Cell biological mechanisms of multidrug resistance in tumor
8. The multidrug resistance gene in gene therapy of cancer and hematopoietic disorders
9. Overexpression of a novel transporter gene in a multidrug resistance human lung cancer cell line
10. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
11. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
12. P-gp and MRP activities in relation to treatment outcome in acute myeloid leukemia
13. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells
14. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport
15. ATP-and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1
16. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplain-resistant human cancer cell lines with decreased drug accumulation
17. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
18. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells
19. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily
20. Export pumps for anionic conjugates encoded by MRP genes
21. MRP3, an organic anion transporter able to transport anti-cancer drugs
22. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells
23. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
24. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs
25. The multidrug resistance protein 5 (MRP5) functions as an ATP-dependent export pump for cyclic nucleotides
26. Palliative cytoreduction in refractory acute leukemia: A retrospective study of 57 adult patients
27. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: The JALSG-AML92 study
28. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia
29. Third intensive postremission chemotherapy in adults with acute myeloid leukemia
30. Varying intensity of postremission therapy in acute myeloid leukemia
31. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia
32. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
33. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study
34. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study
35. Transplantation of unpurged autologous bone-marrow in acuate myeloid leukaemia in first remission
36. Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non-isotopic quantitative cDNA polymerase chain reaction
37. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML
38. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia
39. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia
40. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia
41. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse
42. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: The impact on MRP activity
43. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells
44. Classification of acute leukemia
45. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines and normal hematopoietic CD34+ peripheral blood cells
46. Pharmacology of L-660, 711 (MK-571): A novel potent and selective leukotriene D4 receptor antagonist
47. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report
48. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia
49. Export pumps for anionic conjugates encoded by MRP genes
50. MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuole of Hep G2 cells
51. Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication
52. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
53. Treatment of poor prognosis AML patients using PSC833 (valdospar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)